Chiome Bioscience Begins Phase I Trial for Cancer Drug

Chiome Bioscience Inc. (JP:4583) has released an update.

Chiome Bioscience Inc. has initiated a Phase I clinical trial for their novel antibody drug conjugate, ADCT-701, targeting rare neuroendocrine tumors and carcinomas, with the first patient already dosed. The trial, sponsored by the National Cancer Institute, aims to establish the safe dosage and assess the drug’s pharmacokinetics and safety. ADCT-701, which includes Chiome’s cancer therapeutic antibody LIV-1205, is expected to selectively kill cancer cells due to its high efficacy and target selectivity.

For further insights into JP:4583 stock, check out TipRanks’ Stock Analysis page.